Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jul 23, 2026
Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript
08:16pm, Thursday, 30'th Oct 2025
Apellis Pharmaceuticals, Inc. ( APLS ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Eva Stroynowski Cedric Francois - Co-Founder, President, CEO & Director David Acheson - E
Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
10:35am, Thursday, 30'th Oct 2025
While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its k
Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
09:16am, Thursday, 30'th Oct 2025
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to a loss of $0.46 per share a year ago
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
07:05am, Thursday, 30'th Oct 2025
WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.
Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth
11:05am, Thursday, 23'rd Oct 2025
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robus
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
07:00am, Thursday, 16'th Oct 2025
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced t
Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders
04:34pm, Tuesday, 30'th Sep 2025
Apellis Pharmaceuticals maintains a strong "Buy" rating for me, driven by robust SYFOVRE sales and recent EMPAVELI FDA approvals for rare kidney diseases. APLS is expanding SYFOVRE's potential with a
Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript)
12:55pm, Tuesday, 09'th Sep 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Baird Global Healthcare Conference September 9, 2025 10:15 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy Sull
Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
11:20am, Thursday, 04'th Sep 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Cantor Global Healthcare Conference 2025 September 4, 2025 8:35 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy
Apellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
11:24am, Wednesday, 03'rd Sep 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:45 AM EDT Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Ex
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 27'th Aug 2025
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor con
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
12:12pm, Thursday, 14'th Aug 2025
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
04:23am, Saturday, 02'nd Aug 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Caroline R. Baumal - Chief Medical Officer Cedric Francois - Co-Founder, Pre
Apellis Pharmaceuticals: The Picture Becomes Clearer
02:29pm, Friday, 01'st Aug 2025
Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet since I looked at this biopharma name earlier this year, warranting a fresh look at the stock. Recent approvals fo
